293 related articles for article (PubMed ID: 30794092)
1. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
[TBL] [Abstract][Full Text] [Related]
2. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
[TBL] [Abstract][Full Text] [Related]
3. Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product.
Seo N; Huang Z; Kuhns S; Sweet H; Cao S; Wikström M; Liu J
Biologicals; 2020 Nov; 68():79-91. PubMed ID: 32888776
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma.
Shi Y; Zhang Q; Han X; Qin Y; Ke X; Su H; Liu L; Fu J; Jin J; Feng J; Hong X; Zhang X; Wu D; Jiang B; Dong X
Chin J Cancer Res; 2021 Jun; 33(3):405-416. PubMed ID: 34321836
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
6. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
Zhang L; Yu L; Xu Y; Qin P; Shen P; Liu K; Fei M; Wang H; Cao Y; Lu L; Gao W; Zhang Z
Anal Bioanal Chem; 2023 Jul; 415(17):3341-3362. PubMed ID: 37162525
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
8. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
[TBL] [Abstract][Full Text] [Related]
9. Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method.
Kim H; Hong E; Lee J; Hong S; Kim J; Cho M; Kim Y; Yoo T
BioDrugs; 2023 Jul; 37(4):569-581. PubMed ID: 37060541
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
[TBL] [Abstract][Full Text] [Related]
11. Analytical and functional similarity of biosimilar Elizaria® with eculizumab reference product.
Gusarova V; Degterev M; Lyagoskin I; Simonov V; Smolov M; Taran S; Shukurov R
J Pharm Biomed Anal; 2022 Oct; 220():115004. PubMed ID: 35988306
[TBL] [Abstract][Full Text] [Related]
12. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
Saleem R; Cantin G; Wikström M; Bolton G; Kuhns S; McBride HJ; Liu J
Pharm Res; 2020 May; 37(6):114. PubMed ID: 32476063
[TBL] [Abstract][Full Text] [Related]
13. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
Nupur N; Chhabra N; Dash R; Rathore AS
MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
[TBL] [Abstract][Full Text] [Related]
14. Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product.
Seo N; Guan X; Wang T; Chung HSH; Wikström M; Padaki R; Kalenian K; Kuhns S; Matthies K; Crouse-Zeineddini J; Wong HY; Ng M; Foltz IN; Cao S; Liu J
Ophthalmol Ther; 2024 May; 13(5):1303-1320. PubMed ID: 38507189
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.
Wang H; Wu L; Wang C; Xu J; Yin H; Guo H; Zheng L; Shao H; Chen G
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):790-801. PubMed ID: 33860202
[TBL] [Abstract][Full Text] [Related]
16. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin
Xie L; Zhang E; Xu Y; Gao W; Wang L; Xie MH; Qin P; Lu L; Li S; Shen P; Jiang W; Liu S
BioDrugs; 2020 Jun; 34(3):363-379. PubMed ID: 32072477
[TBL] [Abstract][Full Text] [Related]
17. Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience.
Deng W; Yang S; Yang C; Chen H; Huang G; Wu H; Chen J
J Oncol Pharm Pract; 2022 Jul; ():10781552221110470. PubMed ID: 35786067
[TBL] [Abstract][Full Text] [Related]
18. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases.
Jurczak W; Cohen S; Illidge TM; Silva AD; Amersdorffer J
Future Oncol; 2019 Dec; 15(36):4223-4234. PubMed ID: 31718287
[TBL] [Abstract][Full Text] [Related]
19. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.
Hutterer KM; Polozova A; Kuhns S; McBride HJ; Cao X; Liu J
BioDrugs; 2019 Jun; 33(3):321-333. PubMed ID: 30972630
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
